Treatment for Freckles, Vitiligo, and Hyperpigmentation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Pigmentation disorders of the skin are among the most common dermatological concerns worldwide, affecting people of all Fitzpatrick skin types but disproportionately impacting those with skin types III–VI, in whom conditions such as melasma, post-inflammatory hyperpigmentation, and vitiligo cause significant psychosocial distress, impaired quality of life, and economic burden from lost income and treatment costs.

Melanocyte biology underpins all pigmentation conditions. Melanocytes — dendritic melanin-producing cells residing in the basal layer of the epidermis — synthesise melanin via the enzyme tyrosinase, catalysing L-tyrosine to melanin via DOPA intermediate. Melanin is packaged into melanosomes and transferred via dendritic extensions to surrounding keratinocytes, producing visible skin colour. UV radiation, alpha-melanocyte stimulating hormone (alpha-MSH) via the MC1R receptor, endothelin-1, and stem cell factor (SCF) are the primary physiological stimulants of melanin production. Oestrogen, progesterone, and inflammatory cytokines (IL-1, prostaglandins) can also upregulate melanogenesis — explaining melasma's hormonal triggers.

The major hyperpigmentation disorders are clinically and pathophysiologically distinct:

• Ephelides (freckles): Small (1–5 mm), tan to reddish-brown flat macules on sun-exposed skin, driven by MC1R gene variants that increase UV sensitivity of melanocytes. Fade in winter (melanin production decreases without UV stimulus) and darken in summer — a key distinguishing feature. Most common in Fitzpatrick types I–II with red or fair hair; autosomal dominant inheritance pattern.
• Solar lentigines (actinic lentigines): Larger (5–20 mm), persistent, flat brown to dark brown macules on chronically sun-exposed areas (dorsal hands, face, shoulders). Unlike ephelides, they do not fade in winter. Represent focal proliferation of melanocytes plus increased melanin density driven by cumulative UV damage; increase in number and size with age.
• Melasma: Symmetrical brown-grey patches on the centrofacial area (cheeks, forehead, upper lip, chin) with a blotchy, confluent pattern. Driven by oestrogen/progesterone stimulation of melanocytes (pregnancy — 'chloasma'; combined oral contraceptive pill), UV exposure, thyroid dysfunction, and genetic predisposition. Primarily affects women (90%) of reproductive age; Fitzpatrick types III–V are most susceptible. Wood's lamp examination and dermoscopy differentiate epidermal (enhances under Wood's lamp) from mixed or dermal melasma.
• Post-inflammatory hyperpigmentation (PIH): Brown to grey-brown flat pigmentation at the site of resolved skin inflammation (acne, eczema, psoriasis, insect bites, burns, laser procedures). Formed by excess melanin deposition in keratinocytes (epidermal PIH) or melanin-laden macrophages in the dermis (dermal PIH). Epidermal PIH responds better to treatment than dermal PIH.
• Vitiligo: An autoimmune condition in which cytotoxic T lymphocytes destroy melanocytes, producing well-demarcated, milk-white macules and patches on skin and mucous membranes. Affects approximately 1–2% of the global population regardless of skin type, age, or sex. Associated with other autoimmune conditions (Hashimoto thyroiditis, type 1 diabetes, alopecia areata, Addison's disease). Two major clinical subtypes: non-segmental vitiligo (bilateral, symmetric, progressive) and segmental vitiligo (unilateral, follows a dermatome, earlier plateau in progression).

Treatment strategies are tailored to each pigmentation disorder type, its depth (epidermal versus dermal), Fitzpatrick skin type, and extent of involvement:

• Ephelides (freckles): Treatment motivated by cosmetic preference. Respond excellently to Q-switched lasers and IPL due to superficial epidermal location. Topical lightening agents provide modest fading but lesions typically recur with UV re-exposure unless strict photoprotection is maintained.
• Solar lentigines: More resistant to topical agents than freckles due to higher melanocyte density and persistent UV-driven proliferation. Q-switched 532 nm Nd:YAG laser, Q-switched alexandrite 755 nm, and picosecond lasers achieve excellent clearance in 1–2 sessions. IPL is effective for multiple lesions across large surface areas (dorsal hands, shoulders).
• Melasma: The most challenging hyperpigmentation to treat; tendency to recur with even minimal UV exposure. Requires a multimodal approach: topical depigmenting agents + photoprotection + adjunctive procedures. Distinguishing epidermal from dermal/mixed melasma guides treatment selection (epidermal responds better to topicals and lasers; dermal melasma requires longer treatment duration).
• Post-inflammatory hyperpigmentation: Treat the underlying inflammatory condition first (acne, eczema). Epidermal PIH responds well to topical retinoids, azelaic acid, niacinamide, and tranexamic acid over 3–6 months. Dermal PIH (grey-brown colour) is more treatment-resistant; may require Q-switched laser with caution in skin types III–VI to avoid paradoxical darkening.
• Vitiligo (non-segmental): Treatment aims to halt progression (immunosuppression) and achieve repigmentation. Active vitiligo (expanding lesions) requires systemic immunosuppression or immunomodulation; stable vitiligo (no new lesions for 6 months or longer) is the prerequisite for phototherapy and surgical grafting procedures.
• Segmental vitiligo: After stabilisation, surgical grafting (suction blister epidermal grafting, melanocyte-keratinocyte transplantation) produces excellent repigmentation results due to its early plateau in disease activity.
• Periorbital hyperpigmentation: Multifactorial (vascular, structural, post-inflammatory); managed with topical vitamin K, caffeine, niacinamide, hyaluronic acid fillers (for tear trough hollowing), and Q-switched lasers for melanin-driven pigment.

Patient selection for each treatment modality depends on skin type, diagnosis, extent of disease, medical history, and treatment goals:

Topical depigmenting agents are appropriate for all Fitzpatrick skin types and most hyperpigmentation conditions. Hydroquinone should be avoided in pregnancy (Category C). Topical retinoids (tretinoin, adapalene) are contraindicated in pregnancy. Azelaic acid and niacinamide are safe in pregnancy and preferred alternatives for gestational melasma (chloasma).

Q-switched laser and IPL for freckles and lentigines are best suited to Fitzpatrick types I–III. In types IV–VI, aggressive laser settings risk paradoxical post-treatment hyperpigmentation — test patch 4–6 weeks before full treatment is mandatory. Avoid treating tanned skin. Isotretinoin users should complete their course and wait 6 months before ablative or resurfacing laser procedures.

NB-UVB phototherapy for vitiligo is appropriate for:

• Non-segmental vitiligo involving more than 20% body surface area (too extensive for targeted phototherapy).
• Active or stable vitiligo on face, neck, and trunk (best response sites; acral areas — hands, feet — respond poorly to NB-UVB).
• Patients with concurrent psoriasis or atopic dermatitis may benefit from NB-UVB for both conditions simultaneously.
• Contraindicated in personal or family history of melanoma; relative contraindication in xeroderma pigmentosum or photosensitising drug use.

Surgical grafting procedures for vitiligo require:

• Confirmed disease stability — no new lesions or expansion of existing lesions for a minimum of 6 months (ideally 12 months for suction blister grafting).
• Absence of koebnerisation (tendency for new vitiligo lesions to appear at sites of skin trauma — a positive Koebner phenomenon contraindications grafting).
• Age typically above 12–14 years for cooperation with the grafting procedure.

Oral tranexamic acid (250 mg twice daily) for melasma: avoid in patients with history of thromboembolic disease, deep vein thrombosis, pulmonary embolism, or thrombophilia. Screen for risk factors before prescribing; maximum treatment duration typically 3–6 months with a treatment-free interval.

Topical depigmenting and lightening agents:

• Hydroquinone (HQ) 2–4%: The most extensively studied topical depigmenting agent. Inhibits tyrosinase, the rate-limiting enzyme of melanogenesis, reducing melanin synthesis in melanocytes. Apply twice daily to hyperpigmented areas. Maximum continuous use: 3–6 months to avoid risk of ochronosis (paradoxical permanent darkening — rare, mostly reported with prolonged high-concentration use in dark skin types).
• Triple combination (Kligman formula / Tri-Luma): The gold-standard topical therapy for melasma — hydroquinone 4% + tretinoin 0.05% (comedolytic, increases epidermal turnover) + fluocinolone acetonide 0.01% (low-potency steroid to reduce retinoid/HQ-induced irritation and suppress melanocyte stimulation). Applied once daily at night to melasma areas. Superior to any single agent alone. Licensed as Tri-Luma (US) or available as individually compounded components.
• Azelaic acid 15–20%: Competitive inhibitor of tyrosinase with anti-inflammatory and mild exfoliating properties. Safe in pregnancy. Particularly effective for PIH and rosacea-associated hyperpigmentation. Apply twice daily; takes 12–16 weeks for full effect. FDA-approved for rosacea; widely used off-label for melasma and PIH.
• Kojic acid 1–4%: Fungal-derived tyrosinase inhibitor; often combined with HQ or azelaic acid. May cause contact sensitisation with prolonged use; patch test recommended.
• Niacinamide (vitamin B3) 4–5%: Inhibits melanosome transfer from melanocytes to keratinocytes (interferes with the transfer mechanism without affecting melanin synthesis). Anti-inflammatory, barrier-improving, safe in pregnancy, and non-irritating. Widely available in over-the-counter serums and moisturisers.
• Tranexamic acid (topical 2–5%; oral 250 mg twice daily): Emerging evidence supports both topical and oral tranexamic acid for melasma and PIH. Mechanism: inhibits plasminogen activator in keratinocytes, reducing UV-induced prostaglandin production that stimulates melanogenesis. A 2020 meta-analysis (J Dermatol Treat) confirmed tranexamic acid significantly reduces MASI (Melasma Area and Severity Index) scores versus placebo.

Chemical peels: Superficial peels (glycolic acid 20–70%, mandelic acid 20–40%, salicylic acid 20–30%, lactic acid) accelerate epidermal turnover and enhance delivery of topical lightening agents. Medium-depth TCA 20–30% and Jessner-TCA combination peels address dermal melasma components. Series of 4–8 peels at 2–4 week intervals; caution in skin types IV–VI due to PIH risk.

Laser treatments:

• Q-switched Nd:YAG (1064 nm and 532 nm): Selective photothermolysis targeting melanin. 532 nm for epidermal lesions (freckles, lentigines, epidermal melasma); 1064 nm for deeper pigment and safer in darker skin types. Low-fluence Q-switched Nd:YAG (LFTONING) at 1064 nm is a widely used protocol in Asian skin for melasma without inducing PIH.
• Q-switched alexandrite (755 nm) and picosecond lasers (Picosure, Enlighten): Picosecond pulse durations (10–12 seconds) shatter melanosomes more effectively than nanosecond Q-switched pulses, with less thermal damage, faster healing, and lower PIH risk in darker skin types. Excellent for solar lentigines and tattoo removal.
• Intense Pulsed Light (IPL) 515–1200 nm: Broad-spectrum light targeting melanin and haemoglobin simultaneously; treats freckles, lentigines, redness, and textural irregularities in a single session. Effective for widespread sun damage over large areas. Multiple sessions (3–6) required. Not suitable for skin types V–VI.

Vitiligo-specific treatments:

• Narrowband UVB (NB-UVB, 311 nm) phototherapy: First-line phototherapy for non-segmental vitiligo. Administered 2–3 times per week; dose titrated by skin response. 200 or more sessions may be needed for significant repigmentation, which begins with perifollicular (hair follicle-associated) pigmentation dots. Best response: face and neck; poor response: acral sites (hands, feet, lips, fingertips).
• Excimer laser (308 nm): Targeted UVB for localised vitiligo patches; higher fluences achievable than NB-UVB. Reduces treatment burden for small, discrete patches and avoids irradiating surrounding normal skin.
• Ruxolitinib cream 1.5% (Opzelura — JAK1/2 inhibitor): FDA-approved in 2022 for non-segmental vitiligo in patients 12 years and older. Applied twice daily to vitiliginous areas. The TRuE-V phase 3 trials demonstrated 30% face F-VASI90 response at 24 weeks versus 8% with vehicle. Mechanism: blocks JAK-STAT signalling that drives autoimmune melanocyte destruction.
• Suction blister epidermal grafting (SBEG): A surgical repigmentation technique for stable vitiligo. Suction cups applied to donor skin (normal skin on thigh or buttock) for 1–3 hours raise blisters; the epidermal blister roof (containing melanocytes and keratinocytes) is transferred to a similarly sized recipient site on the vitiliginous patch prepared by dermabrasion or CO₂ laser ablation. Excellent repigmentation rates for segmental vitiligo (80–90%) and stable non-segmental patches; minimal scarring and no anaesthesia in most cases.
• Melanocyte-keratinocyte transplantation procedure (MKTP): Harvested donor skin is enzymatically dissociated into a melanocyte-keratinocyte cell suspension and sprayed onto a large dermabrasion-prepared recipient vitiliginous area. Capable of treating large areas (up to 100 cm²) in a single session. Success rates of 80–90% for stable vitiligo with appropriate patient selection.

Photoprotection — mandatory for ALL conditions: SPF 50+ broad-spectrum UVA/UVB sunscreen applied daily (even on cloudy days) is the single most important intervention to prevent worsening of any pigmentation condition, prevent laser treatment-induced PIH, and maintain results of depigmenting therapy. Re-application every 2 hours with outdoor sun exposure. Physical blockers (zinc oxide, titanium dioxide) are preferred over chemical filters in sensitive or hormonally influenced skin (melasma).

Effective treatment of pigmentation disorders delivers significant clinical, psychosocial, and cosmetic benefits:

• Skin tone evenness and cosmetic improvement: Topical depigmenting agents, chemical peels, and laser/light treatments can achieve 50–90% reduction in pigmentation intensity for ephelides, lentigines, and melasma, producing a more even, luminous skin tone. Kligman triple combination achieves MASI score reduction of 70–80% in melasma at 12 weeks versus 30–40% with HQ monotherapy.
• Durable repigmentation in vitiligo: Surgical procedures (SBEG, MKTP) achieve repigmentation rates of 80–90% in stable segmental vitiligo with colour matching equivalent to surrounding skin in the majority of cases. NB-UVB and JAK inhibitor therapy (ruxolitinib) achieve meaningful repigmentation in 30–50% of non-segmental vitiligo patients, with an ongoing treatment requirement to maintain results.
• Psychological and quality-of-life benefit: Dermatology Life Quality Index (DLQI) scores improve significantly with effective pigmentation treatment. In vitiligo specifically, the Vitiligo Impact Scale demonstrates that active repigmentation — even partial — produces profound improvements in self-esteem, social confidence, and reduced stigma, particularly in cultures where skin colour is heavily socially significant.
• Prevention of further darkening: Consistent SPF 50+ photoprotection combined with topical antioxidants (vitamin C, vitamin E) prevents UV-triggered worsening of melasma, freckles, and lentigines, maintaining treatment results and preventing new lesion development.
• Treatment of PIH at source: Treating the underlying inflammatory condition causing PIH (acne, eczema) prevents new pigmented macules from forming, while topical retinoids and azelaic acid accelerate resolution of existing PIH macules.
• Accessible treatment options: Effective first-line treatments — SPF 50+ sunscreen, topical niacinamide, azelaic acid, and adapalene — are available over the counter at low cost, making evidence-based pigmentation management accessible at all healthcare levels.

Each treatment modality carries specific risks that must be disclosed and minimised with appropriate technique and patient selection:

Topical depigmenting agents:

• Hydroquinone: Contact dermatitis (1–3%); paradoxical ochronosis (permanent blue-black hyperpigmentation) with prolonged use of high concentrations (5–10%) over many months — virtually absent with correct 4% dosing for 3–6 months. Reproductive risk: avoid in pregnancy.
• Topical retinoids (tretinoin, adapalene): Retinoid dermatitis — erythema, peeling, stinging, and photosensitivity — especially in the first 4 weeks. Teratogenic: contraindicated in pregnancy (Category C/D); patients must use effective contraception.
• Azelaic acid: Mild stinging or tingling on application in the first 1–2 weeks; rare contact sensitisation. Generally very well tolerated; safe in pregnancy and breastfeeding.
• Oral tranexamic acid: GI side effects (nausea, diarrhoea) in 5–10% of patients. Very rare but serious: deep vein thrombosis and pulmonary embolism — screen for thromboembolic risk factors before prescribing. Avoid in pregnancy.

Laser and IPL risks:

• Post-treatment PIH (paradoxical darkening): The most clinically important complication in patients with skin types III–VI. Caused by laser-induced thermal injury triggering melanocyte upregulation. Risk substantially reduced by: mandatory test patch 4–6 weeks before treatment, pre-treatment priming with topical HQ for 4 weeks, treating only non-tanned skin, using lower fluences, and post-treatment SPF 50+ from day 1.
• Scarring: rare with correctly calibrated parameters in experienced hands; far higher risk with inappropriate fluences in inexperienced operators.
• Hypopigmentation (laser-induced): permanent loss of pigment at treatment sites, more common with high-fluence nanosecond Q-switched lasers in darker skin types.
• Blistering, crusting, and transient erythema: expected after Q-switched laser for lentigines; self-resolves within 7–10 days with appropriate wound care.

NB-UVB phototherapy risks:

• Erythema (sunburn): dose-related; managed by dose reduction and increasing treatment intervals.
• Polymorphic light eruption (PLE) in the first few weeks of NB-UVB in susceptible individuals.
• Theoretical long-term skin cancer risk from cumulative UV exposure: observed data from large vitiligo cohorts do not show clinically significant elevated melanoma risk with NB-UVB up to 500 sessions, but ongoing monitoring is recommended.

Surgical grafting risks:

• Koebner phenomenon: new vitiligo lesions appearing at donor and/or recipient wound sites — risk reduced by confirming disease stability before surgery.
• Cobblestone or variegated appearance at recipient site if graft take is patchy — managed with additional sessions or laser resurfacing.
• Donor site hyperpigmentation or scarring: generally minimal with SBEG; slightly higher with STSG (split-thickness skin grafting).

Pigmentation conditions are chronic, relapsing disorders requiring long-term follow-up and active maintenance to sustain treatment gains.

Topical depigmenting agents — response monitoring: Initial clinical response to topical agents (HQ, triple combination, azelaic acid) is typically visible at 6–8 weeks, with maximum benefit at 16–24 weeks. Photographic documentation at baseline, 8 weeks, and 16 weeks allows objective assessment using the MASI score (melasma) or Physician Global Assessment (PGA) for PIH. If no meaningful improvement at 12 weeks, reassess: check application technique, photoprotection compliance, and whether underlying trigger (OCP, thyroid dysfunction) has been addressed.

Transition to maintenance: After achieving satisfactory pigment lightening, taper active depigmenting agents (HQ is not recommended for continuous use beyond 6 months) and transition to maintenance with: topical retinoid (adapalene 0.1% or tretinoin 0.025%, every other night), niacinamide 5%, azelaic acid 10–15%, SPF 50+ daily.

Laser and IPL follow-up: Post-treatment review at 4–6 weeks to assess response, healing, and any PIH development. Additional sessions at 4–6 week intervals if incomplete clearance. Strict post-procedure photoprotection: SPF 50+ applied from the morning after treatment; avoid direct sun for minimum 2 weeks. Erythema, crusting, and mild oedema resolve within 7–10 days with simple wound care (petroleum jelly/Vaseline, gentle cleansing).

NB-UVB for vitiligo — monitoring: Response assessment every 3 months using total body vitiligo surface area estimation (VASI or VETF scoring). Erythema at treatment sites signals dose titration is needed. Ophthalmological review recommended annually in patients receiving NB-UVB with facial involvement (protective goggles worn during all sessions are mandatory). Genital shielding required during NB-UVB to reduce cumulative genital mucosal UV exposure.

Vitiligo long-term monitoring:

• Screen for associated autoimmune conditions annually: thyroid function tests (TSH, free T4 — Hashimoto's is the most common comorbidity), fasting glucose and HbA1c (type 1 diabetes), and full blood count (pernicious anaemia/vitamin B12 deficiency).
• Ruxolitinib cream: review at 24 weeks for facial F-VASI response; monitor for local skin infections and acne at application sites.
• Post-surgical grafting: review at 3, 6, and 12 months; photographs to document repigmentation quality and colour match. Sun protection over grafted areas mandatory.

Melasma triggers — mandatory avoidance: Review current OCP use — switch to progesterone-only pill (mini-pill) if melasma is OCP-triggered. Address thyroid dysfunction. Counsel regarding vitamin D supplementation rather than sun-seeking behaviour to maintain vitamin D levels while maintaining photoprotection.

Treatment costs for pigmentation disorders span a very wide range from low-cost over-the-counter topicals to premium laser and surgical procedures:

Topical agents (monthly costs):

• Generic azelaic acid 15–20%: USD $15–$40 per tube (1–2 tubes per month). Brand-name Finacea/Skinoren: USD $60–$100.
• Hydroquinone 4% cream: generic USD $10–$25; brand-name Tri-Luma (triple combination) USD $150–$250 per tube without insurance in the US. Prescription in India and the UK at significantly subsidised cost.
• Niacinamide 5% serums: USD $8–$30 per bottle (over the counter worldwide).
• Oral tranexamic acid 250 mg: generic INR 50–150/month in India; USD $20–$50/month in the US; generally not covered by insurance for melasma indication.

Chemical peels (per session):

• Superficial glycolic or salicylic peel: USD $80–$250 per session in the US and UK; INR 1,000–3,000 (USD $12–$36) in India at accredited dermatology centres.
• Medium-depth TCA peel: USD $150–$500 per session; requires medical supervision.
• Series of 6 peels total cost: USD $500–$1,500 (US); INR 6,000–18,000 in India.

Laser and IPL (per session):

• Q-switched Nd:YAG (1064/532 nm) for lentigines/freckles: USD $200–$600 per session; 1–3 sessions typically needed.
• Picosecond laser: USD $300–$800 per session; generally 2–4 sessions for significant clearing.
• IPL for sun damage (face or hands): USD $250–$500 per session; 3–6 sessions for full clearing.
• India (accredited dermatology centres): Q-switched laser INR 2,000–8,000 per session; picosecond laser INR 5,000–15,000.

NB-UVB phototherapy:

• Typically delivered 2–3 times weekly over 12–24 months. In the UK, NHS-funded for vitiligo patients referred through dermatology. US: USD $50–$200 per session; 100+ sessions needed; total course USD $5,000–$20,000.
• Home phototherapy units (311 nm NB-UVB panels or handpieces): USD $1,200–$2,500 purchase cost; NHS-funded home units available for some UK patients. Cost-effective versus frequent clinic visits for long-term treatment.

Surgical grafting (SBEG/MKTP):

• US: USD $2,000–$6,000 per session (limited insurance coverage for cosmetic vitiligo procedures).
• India (specialist vitiligo surgery centres, e.g., PGIMER Chandigarh, KPC Medical College): INR 8,000–25,000 (USD $96–$300) per session — representing exceptional value and expertise for medical tourism patients.

Several alternative and complementary strategies — from camouflage to emerging biological therapies — complement or substitute for standard dermatological treatments:

• Camouflage cosmetics: High-coverage, skin-tone-matched cosmetic camouflage (Dermablend, Veil Cover Cream, Covermark) can effectively conceal vitiligo patches, extensive melasma, and PIH, providing immediate cosmetic improvement without medical intervention. Waterproof formulations suitable for daily use. Dermatology nurses and charities (Changing Faces, British Skin Foundation) offer trained camouflage application sessions free of charge in some countries.
• Self-tanning agents for vitiligo: Dihydroxyacetone (DHA) 5–10% — the active ingredient in most self-tanners — reacts with amino acids in the stratum corneum to produce a temporary brown colour lasting 3–7 days. Applied to vitiligo patches to reduce contrast with surrounding normally pigmented skin. Safe, non-prescription, no UV exposure required. Particularly useful for acral and lip vitiligo where phototherapy response is poor.
• Micropigmentation (cosmetic tattooing): Intradermal injection of iron oxide pigments matched to surrounding skin colour. Appropriate for stable lip vitiligo and small stable patches where phototherapy and grafting are not feasible. Results fade over years (average 3–5 years) and must be retouched. Not suitable for active or unstable vitiligo (Koebner risk).
• Afamelanotide (Scenesse) + NB-UVB combination for vitiligo: Afamelanotide is an alpha-MSH analogue delivered as a biodegradable subcutaneous implant. When combined with NB-UVB, phase 2 and 3 RCT data (Grimes et al.) demonstrate superior and faster repigmentation compared to NB-UVB alone. Approved by the EMA in 2014 for erythropoietic protoporphyria; used off-label for vitiligo in several European countries. Not FDA-approved for vitiligo.
• Platelet-rich plasma (PRP) for vitiligo: Emerging evidence from small RCTs supports intralesional PRP injection as an adjunct to NB-UVB for stable vitiligo, with growth factors (PDGF, VEGF, TGF-beta) in PRP proposed to stimulate melanocyte migration and proliferation from follicular reservoirs. Not yet standard of care; results from larger trials awaited.
• Dietary antioxidants: Supplementation with vitamin C (500–1000 mg daily), vitamin E (400 IU daily), and polyphenol-rich foods (green tea, berries, curcumin) may reduce oxidative stress on melanocytes in vitiligo and slow melanin oxidation in hyperpigmented conditions. No substitute for medical therapy but evidence-informed adjuncts with excellent safety profiles.
• Sun protective clothing and behaviour modification: Wide-brimmed hats, UPF 50+ clothing, UV-protective window films for car windscreens, and midday sun avoidance (10 am–4 pm) reduce UV-driven worsening of all pigmentation conditions. For melasma, tinted mineral SPF foundations provide additional visible light and infrared protection beyond standard SPF ratings — increasingly important given evidence that visible light also stimulates melanogenesis in dark skin types.